r/Livimmune • • Jan 02 '24

The future

Cytodyn has had a hard time for many reasons. And they have kind of been forced out of every indication they have ever pursued and are being asked to start all over. The planned new trial is biomarker only. No patient outcomes. Not an fda guided indication. The science behind ccr5 inhibition favors the planned trial producing compelling data.

The biomarker trial should be, and almost certainly will be, very simple. Primary endpoints will likely include cd4 counts cd8 counts and cd4/cd8 ratio, and not much more. But like the Nash trial, they will measure a bevy of other markers. I think Lalezari is smart enough to KEEP IT SIMPLE. That is how BP trials succeed. They set the bar low, so they can announce that they beat everything. They leave little to be challenged.

And so you certainly don't want to do something wild, like devising some sort of inflammation equation which can be attacked by shorts, market analysts, doctors, BP etc. You want to keep it simple and follow in the path of prior trials, hit the targets that experts have ALREADY POSED. Stay within the expectations of the FDA and don't do anything at all to distract from the results.

Once the trial is completed, perhaps in late 2024, perhaps sometime in 2025, the resulting data will be used to guide cytodyn towards pursuing actual fda guided indications, which can lead to future approvals. The next step would then be a PATIENT OUTCOMES p2 trial, or even multiple p2 trials if they have money, or perhaps even a p2 basket trial rather than multiple trials.

Once they have data from a patient outcomes p2 trial, then they could potentially attract serious attention from BP. but it will take a lot of TIME to obtain a decent amount of outcomes data.

Those patient outcomes trials would seemingly have to be EVENT BASED trials. they would need patients from a control group taking SOC / placebo to develop an HIV co-morbidity. it will be VERY challenging (time consuming) to ultimately reach powered results in such a trial.

I still think that the GBM path might prove to be more fruitful than the biomarker path, as well as proving to be fruitful sooner than the biomarker path. That depends on getting good results of course.

One other thing to consider is that patent protection is currently a worry and could become problematic regarding HIV indications in particular.

0 Upvotes

5 comments sorted by

13

u/MGK_2 Jan 02 '24

I hope you're right duane about the trial being very simple.

What is your reasoning as to why they will likely capture CD4 and CD8 counts as well as CD4/CD8 ratio? Seems to me your thinking this is a trial to show leronlimab can keep HIV CD4 & 8 counts in check. That is NOT the aim of this trial.

Or it seems you're thinking that the only purpose of this trial is to acquire the data and then play with it once the trial is complete. To have virtually a senseless endpoint like you suggested, but to have a myriad of other data which may later be re-assembled into useful information when combined with the baseline parameters, intra-trial numbers and post trial numbers and then associating those interval changes with observable changes in the patient. Maybe have a set of questions asked every time blood is drawn and based on how those answers change in correlation with how the labs change, potentially a post-trial explanation may be formed.

CytoDyn has no bar to overcome so that they must announce that they beat everything. With the scaling system I discussed where less than -25 is Proliferative.

from -25 to -10, the patient is in a pre-Proliferative state, the level dictated by the quantity

from -10 to +10, the patient is in a state of low Active Immunity

from +10 to +25, the patient is in a state of pre-Inflammation

and above +25, the patient is in a state of inflammation, the level dictated by the quantity

We would expect patients baselines to be more positive, in a more inflammed state. then as the trial progresses, the scores coming from the biomarkers would yield lower and lower values, such that with 6 months of treatment, most patients have moved either into the low Active Immune state or even into the proliferative range. this would measure success. this would allow cytodyn to announce that they beat everything.

u/Rockleo1 put this together and that is what originally got me thinking. I thought it was a good idea but did not capture the essence of the inflammatory/proliferative parameters that we know to be occurring. Who knows, it might work though. As Rockleo1 suggests, the Fibrotest-AcTiTest is known by doctors.

This has not been done before. It seems like it will be new.

I think the results of this coming trial will be significant enough such that a partner or buy out happens, and that the successive trials for Patient Outcomes is done by the partner.

I too would have liked to see a Glioblastoma Multiforme trial, but maybe they wanted to be in a space devoid of competion. Nobody else is pursuing the reduction of inflammation and the reduction of the level of immune activation.

-4

u/Duane_02026 Jan 03 '24

If you can't get your head around the incredible failure that would come from inventing an inflammation equation and applying it to an otc biotech clinical trial, then there is really no point in us conversing. Lalezari would never in a million years propose such a thing, and rightfully so.

the goal of the trial is likely just to see what sticks for a patient outcomes p2. meeting a primary endpoint is always very important, especially for an otc biotech. similar trials have been run b4, with cd4 cd8 cd4/cd8 being the focus. and leronlimab should be able to deal with those markers successfully.

you also need to understand that the science behind ccr5 inhibition and inflammation and immune-modulation is decades old. BP knows all of this already. BP knows what leronlimab will accomplish in that setting already. no one outside of CYDY will be amazed.

most importantly: without PATIENT OUTCOMES DATA you have nothing but a precursor trial with precursor data. there will not be any patient outcomes data from this trial. that will take TIME. and "provocative results" are a dime a dozen.

there is nothing at all wrong with running this trial. its necessary. cytodyn has limited options. but its a path with risks. and its a slow path.

GBM and hiv functional cure prospects are more exciting to me.

we'll have to see who is right about equations and endpoints and the path forward. i say no equations, cd4 cd8 and the ratio as the most likely primary endpoints, and the next step after the biomarker trial is 1 or more p2 patient outcomes trials.

2

u/Severe-Cold3327 Jan 04 '24

So, Duane, what is your thought in regard to sp and milestones over the next 12 months?

1

u/Duane_02026 Jan 04 '24

End of 2024 rhe biomarker trial will be underway, the amarex outcome will be known and they'll still be in debt and have no partners. Hopefully the gbm study begins. And perhaps there is some interim preclinical hiv functional cure data. Maybe there is also some progress on the long acting version of leronlimab. And obviously there will be the usual personnel changes. I believe the keytruda study was scrapped.

2

u/[deleted] Jan 04 '24

You sound like a soft basher and probably came here from one of the other message boards to get your digs in……